Drug Combination Details
| General Information of the Combination (ID: C92213) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Pemetrexed Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro. Cancer Med. 2017 Aug;6(8):1965-1975. | |||
